Workflow
生物药
icon
Search documents
康弘药业跌2.02%,成交额1.06亿元,主力资金净流出117.29万元
Xin Lang Cai Jing· 2025-10-10 06:31
10月10日,康弘药业盘中下跌2.02%,截至14:13,报35.92元/股,成交1.06亿元,换手率0.42%,总市值 330.94亿元。 资金流向方面,主力资金净流出117.29万元,特大单买入260.92万元,占比2.47%,卖出201.25万元,占 比1.90%;大单买入1200.69万元,占比11.36%,卖出1377.64万元,占比13.03%。 康弘药业今年以来股价涨89.05%,近5个交易日跌2.79%,近20日跌8.72%,近60日涨23.48%。 截至9月30日,康弘药业股东户数2.40万,较上期减少3.67%;人均流通股28624股,较上期增加3.81%。 2025年1月-6月,康弘药业实现营业收入24.54亿元,同比增长6.95%;归母净利润7.30亿元,同比增长 5.41%。 分红方面,康弘药业A股上市后累计派现20.38亿元。近三年,累计派现10.40亿元。 机构持仓方面,截止2025年6月30日,康弘药业十大流通股东中,香港中央结算有限公司位居第四大流 通股东,持股2727.50万股,相比上期减少531.59万股。大成睿享混合A(008269)位居第六大流通股 东,持股1225. ...
苏州创新药研究院揭牌
Su Zhou Ri Bao· 2025-10-02 00:07
9月29日,苏州创新药研究院在苏州生物医药产业园揭牌。中国工程院院士詹启敏,市委副书记、 市长吴庆文,苏州大学党委书记张晓宏、校长张桥,亚盛药业董事长杨大俊,信达生物首席运营官周凯 松出席活动。 吴庆文在致辞时代表苏州市委、市政府对研究院的成立表示祝贺。他说,生物医药是苏州"十年磨 一剑"长期坚守、重点打造的主导产业。成立苏州创新药研究院是苏州持续助推生物医药产业全链条创 新发展的重要举措。希望研究院保持耐心与定力,以创新体制机制统筹链接各类资源,当好技术攻关 的"加速器"、拔尖人才的"孵化器"、成果转化的"连接器",成为苏州生物医药产业的创新策源地。苏州 将持续优化政策供给,主动靠前服务,营造更好环境,全力支持研究院建设发展。 苏州创新药研究院由苏州市政府、苏州工业园区与苏州大学携手共建,将秉持"企业出题、联合解 题、政府助题"理念,聚焦分子靶向药物、生物药、基因与细胞治疗、AI药物研发等前沿领域,开展有 组织科研和有组织转化,致力于解决头部企业技术攻关和人才培养需求,打造"实验室—企业—医院"三 位一体的创新闭环,推进"政产学研医"深度融合。活动中,研究院与亚盛药业、信达生物企业联合创新 中心先后揭牌,苏 ...
康弘药业涨2.00%,成交额1.63亿元,主力资金净流出112.69万元
Xin Lang Cai Jing· 2025-09-30 06:54
Core Viewpoint - Kanghong Pharmaceutical has shown significant stock performance with a year-to-date increase of 95.79%, despite a recent decline over the past 20 days [1][2]. Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported a revenue of 2.454 billion yuan, representing a year-on-year growth of 6.95%, and a net profit attributable to shareholders of 730 million yuan, up 5.41% year-on-year [2]. Stock Market Activity - As of September 30, the stock price of Kanghong Pharmaceutical was 37.20 yuan per share, with a market capitalization of 34.273 billion yuan. The stock experienced a trading volume of 163 million yuan and a turnover rate of 0.65% [1]. - The stock has seen a net outflow of 1.1269 million yuan from major funds, with significant buying and selling activity from large orders [1]. Shareholder Information - As of September 19, the number of shareholders for Kanghong Pharmaceutical increased to 24,900, with an average of 27,573 circulating shares per person, a decrease of 0.74% [2]. - The company has distributed a total of 2.038 billion yuan in dividends since its A-share listing, with 1.04 billion yuan distributed in the last three years [3]. Shareholding Structure - As of June 30, 2025, the top ten circulating shareholders included Hong Kong Central Clearing Limited and several mutual funds, with notable changes in their holdings [3].
华海药业跌2.02%,成交额1.32亿元,主力资金净流入36.33万元
Xin Lang Cai Jing· 2025-09-29 02:01
Core Viewpoint - Huahai Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 15.77% but a recent decline over various trading periods, indicating potential volatility in the market [1][2]. Financial Performance - For the first half of 2025, Huahai Pharmaceutical reported revenue of 4.516 billion yuan, a year-on-year decrease of 11.93%, and a net profit attributable to shareholders of 409 million yuan, down 45.30% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 2.989 billion yuan, with 1.016 billion yuan distributed over the past three years [3]. Stock Market Activity - As of September 29, Huahai Pharmaceutical's stock price was 20.40 yuan per share, with a market capitalization of 30.544 billion yuan [1]. - The stock has seen significant trading activity, with a net inflow of 363,300 yuan from main funds and notable buying and selling volumes over recent days [1]. Shareholder Information - As of September 19, the number of shareholders increased by 28.47% to 67,300, while the average circulating shares per person decreased by 22.16% to 21,624 shares [2]. - Major shareholders include China Europe Medical Health Mixed A, which increased its holdings by 12.234 million shares, and Southern CSI 500 ETF, which also saw an increase in holdings [3].
华海药业跌2.02%,成交额5.32亿元,主力资金净流出3349.47万元
Xin Lang Zheng Quan· 2025-09-25 05:34
Core Viewpoint - Huahai Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.02% and a year-to-date increase of 24.17%, indicating volatility in market performance [1][2]. Financial Performance - For the first half of 2025, Huahai Pharmaceutical reported revenue of 4.516 billion yuan, a year-on-year decrease of 11.93%, and a net profit attributable to shareholders of 409 million yuan, down 45.30% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 2.989 billion yuan, with 1.016 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 19, 2025, the number of shareholders increased by 28.47% to 67,300, while the average circulating shares per person decreased by 22.16% to 21,624 shares [2]. - The top ten circulating shareholders include notable entities such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3]. Market Activity - The stock's trading volume on September 25 was 532 million yuan, with a turnover rate of 1.61% and a total market capitalization of 32.76 billion yuan [1]. - Huahai Pharmaceutical has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on September 9, where it recorded a net buy of -53.101 million yuan [1]. Business Overview - Huahai Pharmaceutical, established on February 28, 2001, and listed on March 4, 2003, specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1]. - The company's revenue composition includes finished drug sales (61.86%), raw materials and intermediates sales (36.75%), and other services [1]. Industry Classification - Huahai Pharmaceutical is classified under the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and chemical preparations, with involvement in AI medicine, generic drugs, innovative drugs, cell therapy, and biomedicine [2].
康弘药业涨2.02%,成交额6250.41万元,主力资金净流入530.03万元
Xin Lang Cai Jing· 2025-09-24 03:24
Core Viewpoint - Kanghong Pharmaceutical's stock has shown significant volatility, with a year-to-date increase of 96.63% but a recent decline in the last five and twenty trading days [1][2]. Group 1: Stock Performance - As of September 24, Kanghong Pharmaceutical's stock price was 37.36 CNY per share, with a market capitalization of 34.42 billion CNY [1]. - The stock experienced a net inflow of 5.30 million CNY from main funds, with large orders accounting for 13.33% of purchases [1]. - The stock has seen a 5.70% decline over the last five trading days and an 8.27% decline over the last twenty trading days [1]. Group 2: Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported a revenue of 2.45 billion CNY, representing a year-on-year growth of 6.95%, and a net profit of 730 million CNY, up 5.41% year-on-year [2]. - The company has distributed a total of 2.04 billion CNY in dividends since its A-share listing, with 1.04 billion CNY distributed in the last three years [3]. Group 3: Shareholder Information - As of September 10, the number of shareholders for Kanghong Pharmaceutical was 24,700, a decrease of 1.19% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.21% to 27,778 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several mutual funds, with notable changes in their holdings [3].
华海药业涨2.03%,成交额3.08亿元,主力资金净流入3114.70万元
Xin Lang Cai Jing· 2025-09-24 03:15
Core Viewpoint - Huahai Pharmaceutical's stock has shown a year-to-date increase of 25.65%, despite a recent decline of 6.27% over the past five trading days, indicating volatility in its performance [1]. Financial Performance - For the first half of 2025, Huahai Pharmaceutical reported a revenue of 4.516 billion yuan, a year-on-year decrease of 11.93%, and a net profit attributable to shareholders of 409 million yuan, down 45.30% year-on-year [2]. - The company has distributed a total of 2.989 billion yuan in dividends since its A-share listing, with 1.016 billion yuan distributed over the past three years [3]. Stock Market Activity - As of September 24, Huahai Pharmaceutical's stock price was 22.14 yuan per share, with a market capitalization of 33.149 billion yuan and a trading volume of 308 million yuan [1]. - The stock has appeared on the "龙虎榜" (Dragon and Tiger List) twice this year, with the most recent appearance on September 9, where it recorded a net buy of -531 million yuan [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 16.37% to 52,400, while the average number of tradable shares per shareholder increased by 18.71% to 27,781 shares [2]. - Notable institutional shareholders include China Europe Medical Health Mixed Fund, which increased its holdings by 12.234 million shares, and Southern CSI 500 ETF, which also increased its holdings by 2.158 million shares [3].
华海药业股价跌5.08%,金元顺安基金旗下1只基金重仓,持有8.62万股浮亏损失9.83万元
Xin Lang Cai Jing· 2025-09-23 05:29
Group 1 - The core viewpoint of the news is that Huahai Pharmaceutical's stock has experienced a decline of 5.08% over three consecutive days, with the current stock price at 21.28 CNY per share and a total market capitalization of 31.862 billion CNY [1] - Huahai Pharmaceutical, established on February 28, 2001, and listed on March 4, 2003, specializes in the research, production, and sales of various types of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1] - The company's main business revenue composition includes finished drug sales at 61.86%, raw materials and intermediates sales at 36.75%, other sales at 0.78%, and technical services at 0.62% [1] Group 2 - From the perspective of fund holdings, Jin Yuan Shun An Fund has a significant position in Huahai Pharmaceutical, with its Jin Yuan Shun An Medical Health Mixed A Fund (007861) holding 86,200 shares, accounting for 3.07% of the fund's net value [2] - The fund has incurred a floating loss of approximately 98,300 CNY today, with a total floating loss of 103,400 CNY during the three-day decline [2] - The Jin Yuan Shun An Medical Health Mixed A Fund was established on July 29, 2021, with a current scale of 33.4541 million CNY and has achieved a year-to-date return of 23.6% [2]
华海药业跌2.01%,成交额1.66亿元,主力资金净流出2298.83万元
Xin Lang Cai Jing· 2025-09-23 02:05
Core Viewpoint - Huahai Pharmaceutical's stock has experienced fluctuations, with a year-to-date increase of 24.68% but a recent decline in the last five trading days by 6.91% [1] Financial Performance - For the first half of 2025, Huahai Pharmaceutical reported revenue of 4.516 billion yuan, a year-on-year decrease of 11.93%, and a net profit attributable to shareholders of 409 million yuan, down 45.30% year-on-year [2] - The company has cumulatively distributed 2.989 billion yuan in dividends since its A-share listing, with 1.016 billion yuan distributed in the last three years [3] Stock Market Activity - As of September 23, Huahai Pharmaceutical's stock price was 21.97 yuan per share, with a market capitalization of 32.895 billion yuan [1] - The stock has seen significant trading activity, with a net outflow of 22.9883 million yuan in principal funds on September 23, and a total trading volume of 166 million yuan [1] Shareholder Structure - As of June 30, 2025, the number of shareholders decreased by 16.37% to 52,400, while the average circulating shares per person increased by 18.71% to 27,781 shares [2] - Among the top ten circulating shareholders, notable changes include an increase in holdings by China Europe Medical Health Mixed A and a decrease by Hong Kong Central Clearing Limited [3] Business Overview - Huahai Pharmaceutical, established on February 28, 2001, and listed on March 4, 2003, specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1] - The company's revenue composition includes 61.86% from finished drug sales, 36.75% from raw materials and intermediates, and 0.78% from other sources [1]
华海药业股价连续3天下跌累计跌幅5.04%,嘉实基金旗下1只基金持5.03万股,浮亏损失5.99万元
Xin Lang Cai Jing· 2025-09-22 07:23
Core Viewpoint - Huahai Pharmaceutical's stock has experienced a decline of 5.04% over the past three days, closing at 22.43 CNY per share with a market capitalization of 33.583 billion CNY [1] Company Overview - Zhejiang Huahai Pharmaceutical Co., Ltd. was established on February 28, 2001, and listed on March 4, 2003. The company specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1] - The revenue composition of the company is as follows: finished drug sales account for 61.86%, raw materials and intermediates sales for 36.75%, other sales for 0.78%, and technical services for 0.62% [1] Fund Holdings - According to data, one fund under Jiashi Fund holds a significant position in Huahai Pharmaceutical. Jiashi Xinhe One-Year Holding Period Mixed A (008664) held 50,300 shares in the second quarter, representing 0.39% of the fund's net value, making it the sixth-largest holding [2] - The fund has incurred a floating loss of approximately 26,700 CNY today, with a total floating loss of 59,900 CNY during the three-day decline [2] Fund Manager Information - The fund manager of Jiashi Xinhe One-Year Holding Period Mixed A (008664) is Yang Yechao, who has been in the position for 9 years and 303 days. The total asset size of the fund is 1.878 billion CNY [3] - During Yang Yechao's tenure, the best fund return was 40.38%, while the worst return was -4.07% [3]